Vor Biopharma Inc. (Vor Bio)

Vor Biopharma Inc., operating as Vor Bio, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for autoimmune diseases. The company's mission is to deliver treatments that restore immune system balance and significantly improve patients' lives, with a vision to become a global leader in targeted therapeutics for autoimmune conditions. Headquartered in Boston, Massachusetts, Vor Bio aims to advance therapies that provide durable, disease-modifying benefits beyond mere symptom control.

The company's primary product candidate is telitacicept, a novel fusion protein. Telitacicept functions as a dual BAFF/APRIL inhibitor, designed to suppress the signaling pathways crucial for the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells. This mechanism reduces autoantibody production, which is a key driver of autoimmune pathology. Telitacicept is being developed for various autoimmune indications, including generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's disease (SjD), and IgA nephropathy (IgAN).

In recent developments, telitacicept received NMPA approval for Sjögren's Disease and conditional approval for IgA Nephropathy in China in June 2026. This follows previous approvals in China for SLE, RA, and gMG. Vor Bio also published an interim analysis of the China Phase 3 trial of telitacicept in IgA Nephropathy in The New England Journal of Medicine in May 2026. Jean-Paul Kress, MD, serves as the Chief Executive Officer and Chairman, having been appointed in mid-2025 as part of a strategic pivot towards autoimmune diseases. As of June 2026, Vor Biopharma maintains a market capitalization of approximately $0.81 billion USD.